SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2012; 53 (Supplement 1):527
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Van Laeken, N.
Right arrow Articles by De Vos, F.
PubMed
Right arrow Articles by Van Laeken, N.
Right arrow Articles by De Vos, F.

Molecular Targeting Probes - Radioactive and Nonradioactive

Radiopharmacy

Simplified analytical HPLC purification of [11C]-raclopride

Nick Van Laeken1, Ken Kersemans1 and Filip De Vos1

1 Laboratory Radiopharmacy, Gent, Belgium

Abstract No. 527

Objectives: Previous research has highlighted the synthesis of [11C]-raclopride by methylation of S(+)-O-desmethylraclopride. Mostly, [11C]-raclopride is purified on a (semi-)preparative HPLC column followed by additional steps to obtain an injectable radiopharmaceutical. We aimed at simplifying the purification and the final preparation of [11C]-raclopride using an analytical C18 column and non-toxic solvents compatible with IV solutions.

Methods: [11C]-raclopride is radiosynthetised by the ‘bubbling method’: gaseous methyl triflate is sent through a solution of 100 µg precursor in 200 µL acetone. The reaction is ended by addition of 800 µL 0.05M ammonium acetate buffer (pH6) and the solution is directly loaded on the column. All separations are performed using an analytical Alltech Alltima C18 column (5 µm 150x4,6 mm), a 1000 µL loop, a mobile phase (pH 6) consisting of 0,05M NH4-Ac buffer/EtOH: 70/30 (V/V) and a flow of 2 mL/min. The fraction containing [11C]-raclopride is collected for 2,5 minutes and diluted 1/3 with physiological saline.

Results: [11C]-raclopride elutes after 10,6 minutes and is separated at baseline level from its precursor. The final solution (15 mL) contains 10% EtOH, suitable for injection. By using an analytical rather than a semi-preparative HPLC column and a solvent suitable for injection, additional purification steps, to reduce the concentration of residual solvents in the final formulation, can be avoided. In our module, the total purification time is reduced from 22 to 12 minutes.

Conclusions: By using an analytical C18 column and 0,05 M NH4-Ac buffer/EtOH: 70/30 (V/V) as a mobile phase, the purification time is drastically reduced and [11C]-raclopride, with a high specific activity and radiochemical purity, is obtained which only requires dilution with isotonic saline before administration to the patient


Figure 01
View larger version (12K):
[in this window]
[in a new window]

 
Quality Control of the production and analytical HPLC purification of [11C]-Raclopride

LOD desmethylraclopride:0.23 µg/mL raclopride:0.21 µg/mL LOQ desmethylraclopride:0.35 µg/mL raclopride:0.71 µg/mL

 




This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Van Laeken, N.
Right arrow Articles by De Vos, F.
PubMed
Right arrow Articles by Van Laeken, N.
Right arrow Articles by De Vos, F.